Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Mar 09, 2022 4:30pm
193 Views
Post# 34500882

RE:Why buy Th today

RE:Why buy Th todayI am shocked, shocked Biobob to see you are unaware of the reason to buy TH today?

But the best reason is that we cannot know for sure when TH might announce they have established proof of concept and seen some preliminary signs of efficacy in the phase 1a. Sure, they might wait until the end of the  phase 1a, which is not too far from now but they could announce it at anytime too. They do not have to wait until the end of the trial and it may be more advantageous to announce it sooner depending on how they are planning to do their next financing. Analyst coverage will accompany any share offering and it will be positive and most likely with Cantor or maybe even with JP Morgan. Maybe others too. It sure seems like they have somethng very interesting with TH-1902 and, if so, they will not be able to keep that under wraps for too much longer.  

Don't get whacked - cover your short now.

Trogarzon wrote:



<< Previous
Bullboard Posts
Next >>